These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 11358811)
41. Distant metastases in ovarian cancer: association with p53 mutations. Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623 [TBL] [Abstract][Full Text] [Related]
42. Molecular pathways in the formation of gliomas. von Deimling A; Louis DN; Wiestler OD Glia; 1995 Nov; 15(3):328-38. PubMed ID: 8586467 [TBL] [Abstract][Full Text] [Related]
43. Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers. Huang CC; Cheng YW; Chen MC; Lin YS; Chou MC; Lee H Environ Mol Mutagen; 2006 Aug; 47(7):527-32. PubMed ID: 16721749 [TBL] [Abstract][Full Text] [Related]
44. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005 [TBL] [Abstract][Full Text] [Related]
45. Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy. Saunders ME; MacKenzie R; Shipman R; Fransen E; Gilbert R; Jordan RC Clin Cancer Res; 1999 Sep; 5(9):2455-63. PubMed ID: 10499619 [TBL] [Abstract][Full Text] [Related]
46. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Lima-Ramos V; Pacheco-Figueiredo L; Costa S; Pardal F; Silva A; Amorim J; Lopes JM; Reis RM Cancer Genet Cytogenet; 2008 Jan; 180(1):14-9. PubMed ID: 18068527 [TBL] [Abstract][Full Text] [Related]
47. Chromosome 10 and 17 deletions and p53 gene mutations in Thai patients with astrocytomas. Put-Ti-Noi S; Petmitr S; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W Oncol Rep; 2004 Jan; 11(1):207-11. PubMed ID: 14654927 [TBL] [Abstract][Full Text] [Related]
49. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Conway K; Edmiston SN; Cui L; Drouin SS; Pang J; He M; Tse CK; Geradts J; Dressler L; Liu ET; Millikan R; Newman B Cancer Res; 2002 Apr; 62(7):1987-95. PubMed ID: 11929815 [TBL] [Abstract][Full Text] [Related]
50. Analysis of the TP53 gene in laser-microdissected glioblastoma vasculature. Kulla A; Burkhardt K; Meyer-Puttlitz B; Teesalu T; Asser T; Wiestler OD; Becker AJ Acta Neuropathol; 2003 Apr; 105(4):328-32. PubMed ID: 12624785 [TBL] [Abstract][Full Text] [Related]
51. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874 [TBL] [Abstract][Full Text] [Related]
52. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. Kaserer K; Schmaus J; Bethge U; Migschitz B; Fasching S; Walch A; Herbst F; Teleky B; Wrba F J Pathol; 2000 Mar; 190(4):450-6. PubMed ID: 10699994 [TBL] [Abstract][Full Text] [Related]
53. Correlation of p53 immunoreactivity and sequencing in patients with glioma. Kyritsis AP; Xu R; Bondy ML; Levin VA; Bruner JM Mol Carcinog; 1996 Jan; 15(1):1-4. PubMed ID: 8561860 [TBL] [Abstract][Full Text] [Related]
54. Detection of somatic TP53 splice site mutations in diffuse astrocytomas. Uno M; Oba-Shinjo SM; de Aguiar PH; Leite CC; Rosemberg S; Miura FK; Junior RM; Scaff M; Nagahashi Marie SK Cancer Lett; 2005 Jun; 224(2):321-7. PubMed ID: 15914282 [TBL] [Abstract][Full Text] [Related]
55. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas. Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631 [TBL] [Abstract][Full Text] [Related]
56. p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Baxendine-Jones J; Campbell I; Ellison D Clin Neuropathol; 1997; 16(6):332-6. PubMed ID: 9401801 [TBL] [Abstract][Full Text] [Related]
57. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Jesien-Lewandowicz E; Jesionek-Kupnicka D; Zawlik I; Szybka M; Kulczycka-Wojdala D; Rieske P; Sieruta M; Jaskolski D; Och W; Skowronski W; Sikorska B; Potemski P; Papierz W; Liberski PP; Kordek R Cancer Genet Cytogenet; 2009 Jan; 188(2):77-82. PubMed ID: 19100509 [TBL] [Abstract][Full Text] [Related]
58. Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Haapasalo H; Isola J; Sallinen P; Kalimo H; Helin H; Rantala I Am J Pathol; 1993 May; 142(5):1347-51. PubMed ID: 7684193 [TBL] [Abstract][Full Text] [Related]
59. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478 [TBL] [Abstract][Full Text] [Related]
60. Higher frequency of p53 gene mutations in diffuse large B-cell lymphoma with MALT component. Tai YC; Tan JA; Peh SC Pathol Int; 2004 Nov; 54(11):811-8. PubMed ID: 15533223 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]